The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors
Abstract
Background: TP53 is the most commonly mutated gene across all cancer types. R175H mutation was considered structural mutation where the mutation causes misfolding of the protein and leads to a significant conformational alterations within p53's DNA binding domain. The aim of this study was to explain the reason why R175H worse the response to immunotherapy by analyzing tumor immune microenvironment through the expression of immune cells and PD‐1. Materials and Methods: Patients diagnosed with metastatic carcinoma, including colorectal cancer (CRC), breast cancer (BRCA), gastric cancer (GC), non‐small cell lung cancer (NSCLC), and 20 other cancer types, treated in a palliative setting at Samsung Medical Center between October 2019 and April 2021, were enrolled. Of these patients, those who underwent TDS analysis (TruSight™ Oncology 500 assay [TSO 500]) were finally analyzed. Results: Of 1770 patients, 1012 (57.2%) harbored genetic alterations in TP53. All mutations were single nucleotide variants (SNVs), and the most frequent SNV was R175H ( n = 84, 7.5%) which was known as one of the most common hotspot TP53 mutation. The overall survival of patients with TP53 R175H mutations was significantly worse following chemotherapy (606 vs. 456 days, p < 0.001) or immunotherapy (822 vs. 350 days, p < 0.001) compared to those with TP53 mutation in other loci. RNA sequencing indicated that the immune response‐related pathways were downregulated in tumors harboring TP53 R175H mutation. Moreover, the expression of CD8(+) T cells PD‐1 were lowered in R175H mutation tumors. In the analysis of TP53 structural domain, compared to those having TP53 mutation in other domain, patients with mutations occurring in the nuclear exporter signal (NES) and E4F1‐binding domains had significantly worse overall survival following chemotherapy (NES: 606 vs. 451 days, p = 0.043; E4F1: 606 vs. 469 days, p = 0.046) and immunotherapy (NES: 822 vs. 403 days, p < 0.001; E4F1: 822 vs. 413 days, p < 0.001). In addition, tumors with TP53 mutation and co‐existing copy number amplification of CCND1, FGF4, and FGF19 in chromosome 11 conferred worse prognosis than those with only TP53 mutation ( p < 0.050). Discussion: Each TP53 mutations indicated differential treatment outcomes following chemotherapy or immunotherapy in patients with metastatic cancer. Functional analysis including RNASeq suggested that TP53 mutation downregulated immune response. Conclusion: Overall, we found each TP53 mutation to indicate different prognoses in patients with metastatic tumors undergoing chemotherapy and ICI treatment. Further validations, including a prospective cohort study or a functional study, would be particularly valuable in advancing the knowledge on this aspect and developing improved prognostic parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TP53 mutations cause poor responses to various therapies 32, 33, including immunotherapy and chemotherapy.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
Self-citationThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Targeting a neoantigen derived from a common TP53 mutation
Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science · doi:10.1126/science.abc8697 · Cited by 367
Research works printed but not linked: 31
- HassinO NatarajNB Shreberk‐ShakedM et al.Different Hotspot p53 Mutants Exert Distinct Phenotypes and Predict Outcome of Colorectal Cancer Patients.2022;13:1‐15. · DOI
- 10.1016/S0304-419X(02)00035-5 · DOI · Paper page
- 10.1038/ncb2641 · DOI · Paper page
- 10.1038/ng.2591 · DOI · Paper page
- 10.1038/nature11404 · DOI · Paper page
- 10.1038/nature11252 · DOI · Paper page
- 10.1038/cdd.2017.180 · DOI · Paper page
- 10.1093/jmcb/mjaa040 · DOI · Paper page
- 10.1038/ng0593-42 · DOI · Paper page
- 10.1093/bioinformatics/btv195 · DOI · Paper page
- 10.1038/nprot.2009.86 · DOI · Paper page
- DobinA DavisCA SchlesingerF et al.STAR: Ultrafast Universal RNA‐Seq Aligner.2013;29:15‐21. · DOI · Paper page
- LiBJBB DeweyCN.RSEM: Accurate Transcript Quantification from RNA‐Seq Data with or without a Reference Genome.2011;12:323. · DOI · Paper page
- 10.1016/S0092-8674(05)80006-6 · DOI · Paper page
- 10.1038/74624 · DOI
- 10.1038/312651a0 · DOI · Paper page
- 10.1111/j.1438-8677.2008.00168.x · doi:10.1111/j.1438-8677.2008.00168.x
- 10.1177/1947601911409747 · DOI · Paper page
- StommelJM MarchenkoND JimenezGS MollUM HopeTJ Wahl GMJTEj.A Leucine‐Rich Nuclear Export Signal in the p53 Tetramerization Domain: Regulation of Subcellular Localization and p53 Activity by NES Masking.1999;18:1660‐1672. · DOI · Paper page
- DerheimerFA ChangC‐W Ljungman MJEJoC.Transcription Inhibition: A Potential Strategy for Cancer Therapeutics.2005;41:2569‐2576. · DOI
- GravinaGL SenapedisW McCauleyD et al.Nucleo‐Cytoplasmic Transport as a Therapeutic Target of Cancer.2014;7:1‐9. · DOI · Paper page
- KauTR WayJC. Silver PAJNRCNuclear Transport and Cancer: From Mechanism to Intervention.2004;4:106‐117. · DOI · Paper page
- NieL HouJ ChuY‐Y et al.Compartmentalized Functions of Epidermal Growth Factor Receptor (EGFR) in Tumorigenesis and Malignant Phenotypes.2021;81:120. · doi:10.1158/1538-7445.am2021-120
- Le CamL LinaresLK PaulC et al.E4F1 Is an Atypical Ubiquitin Ligase that Modulates p53 Effector Functions Independently of Degradation.2006;127:775‐788. · DOI · Paper page
- 10.1158/1535-7163.MCT-06-0336 · DOI · Paper page
- 10.1002/ijc.20818 · DOI
- 10.1038/sj.onc.1202314 · DOI · Paper page
- 10.1038/cdd.2013.17 · DOI · Paper page
- 10.1016/j.ccell.2018.07.004 · DOI · Paper page
- 10.1093/carcin/22.1.89 · DOI
- 10.1002/gcc.2870090407 · DOI
Cited by
(2025) · doi:10.1038/s41467-025-57181-2 · Cited by 34
Bian, S., Bian, H., Koyama, H., Kompaniiets, D., Tse, W., Shah, M. V., Al-Kali, A., Miron, A., Liu, B., & Liu, S. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.131687
Metadata
- Authors
- Kim, J., Jung, J., Kim, K., Lee, J., & Im, Y.
- Affiliations
- Division of Hematology‐Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea
- Innovative Institute for Precision Medicine, Samsung Medical Center Seoul South Korea
- Department of Pathology and Translational Genomics, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2023-04-20
- Volume
- 12
- Issue
- 11
- Pages
- 12438-12451
- ISSN
- 2045-7634
- Cited by
- 38
- References
- 6
- Language
- en
- Funders
- National Research Foundation of Korea (NRF‐2017R1D1A1B03028446, NRF‐2020R1F1A1072616)
- Korea Health Industry Development Institute (HR20C0025)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.